DRTS is surging in anticipation for the new data coming tomorrow

Been watching $DRTS for quite a while and today's move makes complete sense once you understand what's happening tomorrow. Alpha Tau Medical (DRTS) is presenting pancreatic cancer clinical data at Digestive Disease Week (DDW) tomorrow morning - and this isn't just another routine conference appearance. This is the first time ever that Alpha DaRT pancreatic cancer results have been selected for an oral/podium presentation at a major gastroenterology conference. That's a pretty big deal for a company that's been flying under the radar. For those who don't know, Alpha DaRT is their technology for delivering alpha radiation directly into solid tumors - basically a localized radiation therapy that targets the tumor without nuking surrounding tissue. They've been running trials in pancreatic, skin, prostate, and brain cancers. Pancreatic cancer is obviously one of the hardest to treat, so any meaningful efficacy data there gets attention fast. The presentation tomorrow (May 2, 10:30am Central) covers updated results from two first-in-human trials out of Hadassa Medical Center. These trials already informed their U.S. IMPACT study which is actively enrolling, so the data isn't starting from zero - but tomorrow is the first public full readout at a major conference stage. On top of that, they recently got FDA approval to expand IMPACT, got their first European pancreatic patient treated in the ACAPELLA trial in France, and have an ASCO abstract dropping later this month pooling data from 58 pancreatic patients across three studies. It's been a busy few weeks of catalysts stacking up. The stock's been climbing as people connect the dots. Still a small-cap biotech so volatility is the name of the game - but the near-term catalyst is very real and very specific. Not financial advice, do your own DD. But if you're curious what's driving the move today, this is it. Eyes on tomorrow morning.